Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 485 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo: Sterile Saline Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

NCT05468736
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
6 Months to 11 Years
Enrollment
3,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
47
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

NCT05572658
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
60 Years and older
Enrollment
10,994 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
109
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 23, 2026, 6:16 AM EDT
Terminated Phase 4 Interventional Results available

Sodium Supplementation and Growth in Very Low Birth Weight Infants

NCT01795638
View directory record Official record
Conditions
Extreme Immaturity
Interventions
Sodium chloride, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Days to 8 Days
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

NCT03397121
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Mission Viejo, California • Newport Beach, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

NCT02037555
View directory record Official record
Conditions
Cardiac Surgery, Cardiopulmonary Bypass
Interventions
AT-III (Human), Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
41
States / cities
Orange, California • San Francisco, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 23, 2026, 6:16 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04798027
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 23, 2026, 6:16 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

IV Administration of ChromaDex's Niagen® as Compared to NAD+

NCT06382688
View directory record Official record
Conditions
Healthy Aging
Interventions
NAD+ (nicotinamide adenine dinucleotide) IV, Niagen® (nicotinamide riboside) IV, Niagen® (nicotinamide riboside) oral, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
40 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

NCT04659863
View directory record Official record
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

NCT03705234
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
University of Oxford
Other
Eligibility
40 Years and older
Enrollment
16,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2049
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Withdrawn Phase 4 Interventional

Randomized Controlled Trial Comparing Irrisept Versus Normal Saline for Wound Irrigation After Posterior Spine Surgery

NCT05408923
View directory record Official record
Conditions
Lumbar Spine Degeneration, Cervical Spine Degeneration
Interventions
saline 0.9%, (0.05% chlorhexidine gluconate (CHG) in sterile water)
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional

A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder

NCT01629537
View directory record Official record
Conditions
Post Traumatic Stress Disorder (PTSD)
Interventions
Stellate Ganglion Block injection with ropivicane, Placebo Procedure
Procedure
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 23, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Results available

Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide

NCT05033041
View directory record Official record
Conditions
Pregnancy, Cesarean Section, Aspiration
Interventions
Study drug metoclopramide, Study drug placebo administration
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 23, 2026, 6:16 AM EDT
Terminated Not applicable Interventional Results available

Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery

NCT01337739
View directory record Official record
Conditions
Pain
Interventions
Placebo Comparator, Active Comparator
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 23, 2026, 6:16 AM EDT
Recruiting Phase 4 Interventional

Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy

NCT04182997
View directory record Official record
Conditions
Lumbar Disc Herniation
Interventions
Dexamethasone, saline 0.9%
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults

NCT02508194
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
MEDI7510, IIV, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
60 Years to 99 Years
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

NCT01396239
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
AVI-4658 (Eteplirsen), Placebo
Drug · Other
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 13 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

In-office Repair of Chronic Tympanic Membrane Perforations

NCT06448039
View directory record Official record
Conditions
Chronic Tympanic Membrane Perforation
Interventions
Fibroblast Growth Factor 2, Saline control
Drug
Lead sponsor
D. Bradley Welling, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

NCT02873286
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA-BN-RSV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
55 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
12
States / cities
Redding, California • San Diego, California • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 23, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

NCT00912496
View directory record Official record
Conditions
Influenza
Interventions
MF-59, A/Anhui/05, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
637 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia

NCT04849988
View directory record Official record
Conditions
Cervical Dystonia
Interventions
ABP-450, Placebo
Drug
Lead sponsor
AEON Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 23, 2026, 6:16 AM EDT
Withdrawn Phase 2 Interventional

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

NCT01565395
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 23, 2026, 6:16 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

NCT04822701
View directory record Official record
Conditions
COVID-19
Interventions
BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting Phase 2 Interventional

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

NCT03929601
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 6:16 AM EDT